Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Deciphera Pharmaceuticals' Preliminary Unaudited Q4 2023 Qinlock Net Product Revenue Of Approximately $46M, Up 40% Y/Y

Author: Benzinga Newsdesk | January 08, 2024 08:17am
  • Expects to Submit Vimseltinib New Drug Application (NDA) in the Second Quarter of 2024 and Marketing Authorisation Application (MAA) in the Third Quarter of 2024 in Tenosynovial Giant Cell Tumor (TGCT); Commercial Launch Preparations Underway.
  • Expects to Initiate a Phase 2 Proof-of-Concept Study of Vimseltinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD) in the Fourth Quarter of 2024.

Posted In: DCPH


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist